Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
5 minute read
  • Biotech
  • General
  • News

‘Oregon’s First-In-Nation Psilocybin Industry Is Struggling To Find Paying Customers A Year After Launching’ – Marijuana Moment

By Benzinga Newsdesk
June 12, 2:07 PM
https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be

CMPS

Read More
2 minute read
  • ETFs
  • FDA
  • General
  • Movers
  • Psychedelics
  • Specialty ETFs
  • Top Stories

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment

By Aaron Bry
June 5, 3:26 PM
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.

ATAI

Read More
4 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Trading Ideas

Why Lands’ End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Avi Kapoor
June 5, 1:04 PM
Shares of Lands’ End, Inc. (NASDAQ:LE) fell sharply during Wednesday’s session following first-quarter results. Lands’ End reported quarterly…

AMBC

Read More
2 minute read
  • Movers
  • News
  • Psychedelics

What’s Going On With MindMed And Psychedelic Stocks?

By Erica Kollmann
June 5, 10:58 AM
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD). Here's a look at what's moving psychedlic stocks:

ATAI

Read More
1 minute read
  • Markets
  • Movers
  • News
  • Pre-Market Outlook
  • Trading Ideas

DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

By Avi Kapoor
June 5, 8:07 AM
U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday. Shares…

AMC

Read More
2 minute read
  • Markets
  • Movers
  • News
  • Pre-Market Outlook
  • Trading Ideas

Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

By Avi Kapoor
June 5, 5:27 AM
Shares of Stitch Fix, Inc. (NASDAQ:SFIX) rose sharply in today’s pre-market trading following better-than-expected third-quarter financial results. Stitch…

ANNX

Read More
3 minute read
  • Cannabis
  • Emerging Markets
  • Markets
  • News
  • Small Cap

Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch

By Nicolas Jose Rodriguez
May 18, 10:19 AM
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).

ABBV

Read More
2 minute read
  • Markets
  • Media
  • News
  • Trading Ideas

Jim Cramer: This Industrial Company Is ‘Absolutely Terrific’, Recommends Buying Modine Manufacturing

By Avi Kapoor
May 15, 9:18 AM
Regarding Hertz, Jim Cramer said, "I don't want you to sell, and I don't want you to double down. Let's just see if it can't go higher."

AME

Read More
2 minute read
  • Markets
  • Movers
  • News
  • Pre-Market Outlook
  • Trading Ideas

Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

By Avi Kapoor
May 13, 8:31 AM
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday. Shares…

BUR

Read More
2 minute read
  • Biotech
  • General
  • News

Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.

By Benzinga Newsdesk
May 9, 8:56 AM
-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with

MNMD

Posts pagination

1 2 … 26 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service